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The STARD initiative
Sir—In studies of diagnostic accuracy,
the outcomes from one or more tests
under assessment are compared with
outcomes from the reference standard,
both obtained in individuals who are
suspected of having the disorder of
interest. Diagnostic accuracy can be
expressed in many ways, including
sensitivity and specificity, likelihood
ratios, and the diagnostic odds ratio.
There are several potential threats to
the validity and generalisability of
studies of diagnostic accuracy.
Diagnostic studies with specific design
features have been shown to be
associated with biased, optimistic
estimates of diagnostic accuracy
compared with studies without such
deficiencies.1 Complete and accurate
reporting should allow the reader to
detect the potential for bias in the study
and to assess the generalisability and
applicability of the results.
At the 1999 Cochrane Colloquium
meeting in Rome, Italy, the Cochrane
Diagnostic and Screening Test
Methods Working Group discussed the
low methodological quality and
substandard reporting of diagnostic test
assessments. The objective of the
Standards for Reporting of Diagnostic
Accuracy (STARD) initiative formed at
the meeting became the improvement
of the quality of reporting of diagnostic
accuracy studies. After the successful
CONSORT initiative,2 the STARD
initiative aimed to develop a checklist
of items that should be included in 
the report of a study of diagnostic
accuracy.
A STARD steering committee 
(for membership and details see
http://image.thelancet.com/extras/
02cor11089web.pdf) did an extensive
literature search and extracted a list of
75 potential items. Subsequently, the
STARD steering committee convened a
2-day consensus meeting on Sept 16 and
17, 2000, in Amsterdam, Netherlands,
for invited experts including researchers,
editors, methodologists, and
professional organisations. During the
consensus meeting, participants
eliminated and consolidated items to
form a 25-item checklist.
In addition, the STARD group put
substantial effort into the development
of a flow diagram for diagnostic
studies. A flow diagram has the
potential to communicate vital
information about the design of a
study—including method recruitment
and the order of test execution—and
the flow of participants in a transparent
manner.
Potential users field-tested the first
version of the checklist and flow
diagram. The checklist was placed on
the CONSORT website with a call for
comments.
The STARD group received
valuable comments and remarks during
the various stages of evaluation, and
assembled the final, single-page
checklist that is published in the first
issues of 2003 in several journals,
including Radiology, Annals of Internal
Medicine,3 BMJ, Clinical Chemistry,4
and on this journal’s website
(http://image.thelancet.com/extras/
02cor11089web.pdf). A separate
document explaining the meaning and
rationale of each item and briefly
summarising the available evidence is
also published in Annals of Internal
Medicine and Clinical Chemistry.5
The STARD group plans to release
updates of STARD when new evidence
on sources of bias or variability becomes
available. We welcome all comments to
improve the current version.
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Trade concerns must not
be allowed to set the
public health agenda
Sir—In November, 2001, trade
ministers from around the world
agreed to develop mechanisms to
increase access to essential drugs in
the developing world. Through the
Doha Declaration on TRIPS and
Public Health, a firm commitment
was made by all members of the
World Trade Organization (WTO) to
put health above trade concerns,
stating that: “the [TRIPS] Agreement
can and should be interpreted and
implemented in a manner supportive
of WTO Members’ right to protect
public health and, in particular, to
promote access to medicines for all.”1
A year later, those same ministers
met to agree in detail how to put their
statement into practice. Their earlier
promises are not being matched by
action, and the negotiations represent
a tragic U-turn in the health–trade
debate.
Leading industrialised countries are
once again putting immense pressure
on developing countries to accept
dangerous proposals that would limit
their ability to access affordable
medical tools, effectively reversing the
achievement of the Doha Declaration.
The USA, European Union (EU), and
Japan argued that measures “to
protect public health” should be
limited to infectious diseases,
specifically AIDS, tuberculosis, and
malaria. In other words, these
industrialised countries are only
concerned by diseases in the
developing world insofar as they pose
a potential threat to their nationals
and their economic interests, with the
burden on developing countries being
almost incidental. Moreover, since
negotiators insisted that the tools to
respond to them should be limited to
drugs, excluding all other medical
technologies, such as vaccines and
diagnostics.
Most alarmingly, they propose to
exclude the growing burden of non-
infectious disease in the developing
world, where at present millions of
people are dying because they are
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unable to get basic medicines such as
insulin.2 The individual suffering
caused by this growing disease
burden3 contributes enormously to the
social and economic difficulties faced
by most of the world’s population.
3 years after demonstrators in
Seattle put the needs of the majority of
the world firmly at the doorstep of the
WTO,4 very little has changed. Crude
compromises on public health are
being put forward by trade negotiators
with no expertise in the health field.
The US and EU postitions seem to
protect little beyond the interests 
of their drug industries. The duty of
medical professionals to protect the
interests of public health over trade
has never been clearer, nor more vital.
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To date 11 African countries are
receiving Diflucan, namely South
Africa, Botswana, Lesotho, Malawi,
Namibia, Mozambique, Ghana,
Uganda, Tanzania, Rwanda, and
Swaziland. Over three million tablets
have been dispersed. The programme
was expanded to the world’s least
developed countries in June, 2001, 
and several countries will soon be
receiving Diflucan, including Zambia, 
Zimbabwe, Senegal, Côte d’Ivoire,
Ethiopia, and Cambodia. Haiti is
already on the programme. The
programme has also expanded to
include non-governmental institutions.
We would have appreciated being
contacted before such an article was
published in The Lancet.
Konji Sebati
International Philanthropy, Corporate Affairs,
Pfizer Inc, 235 East 42nd Street, New York, 
NY 10017, USA
(e-mail: konji.sebati@pfizer.com)
1 Henry D, Lexchin J. The pharmaceutical
industry as a medicines provider. Lancet
2002; 360: 1590–95.
single funder is the UK Government’s
Department of Health and there are
seven other pharmaceutical funders.
Many of our other industry supporters
produce products that compete with
those made by Pfizer, including
treatments for erectile dysfunction. We
also receive funding from various
charitable trusts and commercial
organisations. The Men’s Health Forum
has never preferentially advocated any
specific treatment for health problems.
As a registered charity, the Forum is
subject to regulation by the Charity
Commission and charity law. 
Our pharmaceutical funders have
always been clear that their support for
the Men’s Health Forum is to increase
men’s awareness of health issues and to
improve the delivery of health services to
men. They have never asked us to
recommend any specific drug or type of
treatment and, if they did, we would act
to preserve our integrity and autonomy.
Ian Banks
Men’s Health Forum, Tavistock House, London
WC1H 9HR, UK
(e-mail: office@menshealthforum.org.uk)
1 Collier J, Iheanacho I. The pharmaceutical
industry as an informant. Lancet 2002; 360:
1405–09.
Pfizer Diflucan Partnership
Program
Sir—In their Medicines, society, and
industry paper (Nov 16, p 1590),1
David Henry and Joel Lexchin
represented several facts erroneously.
They comment that Pfizer’s Diflucan
Partnership Program “has not been so
well received because of the limitations
imposed by sponsors”. However, the
Diflucan Partnership Program (DPP)
has no limit to dollar and time, 
and Pfizer is fully committed to it,
despite the many hurdles we meet,
including very poor infrastructure 
and poor inventory skills, delayed
registration, and drug theft from health
facilities.
The DPP not only provides
treatment for cryptococcal meningitis,
but also for oesophageal candidiasis.
The programme was launched in South
Africa in December, 2000, and was
expanded to all the Southern African
Development Community countries,
with Swaziland, Botswana, and
Lesotho on the programme since
February, 2002.
Authors’ reply
Sir—We are grateful to Konji Sebati for
providing details of the current status
of the Diflucan (fluconazole) donations
in Africa. We congratulate Pfizer for
continuing to support this programme
and for extending it to a number of
countries. We apologise for this
omission from our article.
Our understanding was that Pfizer
originally intended to limit donations
to patients with cryptococcal infections
in South Africa, and extended the
programme after protests from
governments and advocacy groups.
*David Henry, Joel Lexchin
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The pharmaceutical
industry as an informant
Sir—Joe Collier and Ike Iheanacho 
(Nov 2, p 1405)1 raise many pertinent
points about how the pharmaceutical
industry provides information to sectors
of society. They are, however, incorrect
to suggest that the Men’s Health Forum
is an example of a patients’ advocacy
group inappropriately funded by a major
pharmaceutical company. They imply
that Pfizer exerts an undue influence on
the Forum that poses a threat to rational
prescribing.
Pfizer is just one of many funders of
the Men’s Health Forum; the largest
Sir—Joe Collier and Ike Iheanacho1 are
right that the pharmaceutical industry
can exert great influence by supplying
information to medical practitioners and
researchers. Although their comments
are generally well balanced, they tend to
suggest that bias is a result of all
industry-sponsored research. The only
proof they offer to lend support to this
contention is from anecdotal reports
about specific issues—for example, 
the dispute about third-generation
contraceptives.
The influence of industry funding can
only be understood with knowledge
about the total number of the sponsored
research projects, including the ones
that are well designed and reported in an
unbiased way. Such knowledge might
show that any bias is much less
prevalent than is suggested by just
focusing on the irregularities that have
occurred. Of course, these irregularities
need to be prevented at all costs.
Unfortunately the blame cannot be
exclusively laid with “the industry”;
badly designed or biased studies are first
approved by scientific review boards and
ethical committees in hospitals and
academic institutions. We as academic
researchers and physicians are, there-
fore, accomplices in the irregularities
Collier and Iheanacho refer to. The
quality-control system that exists in
internal scientific review and ethical
approval has, therefore, to be
strengthened. The Dutch law on clinical
